STRONGBRIDGE BIOPHARMA PLC : Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits (form 8-K)

Item 1.01.                     Entry into a Material Definitive Agreement.

On September 16, 2020, Strongbridge Biopharma plc (the "Company") entered into an underwriting agreement (the "Underwriting Agreement") with Jefferies LLC and Stifel, Nicolaus & Company, Incorporated, as representatives of the several underwriters named in Schedule A thereto (the "Underwriters"), relating to the public offering (the "Offering") of 11,111,111 ordinary shares of the Company, $0.01 par value per share, at a price to the public of $2.25 per share. The net proceeds to the Company from the Offering, after deducting the underwriting discounts and commissions and estimated offering expenses payable by the Company, are expected to be approximately $23.1 million. The Offering is expected to close on or about September 21, 2020, subject to customary closing conditions. Under the terms of the Underwriting Agreement, the Company has also granted the Underwriters a 30-day option to purchase up to an additional 1,666,666 ordinary shares at the public offering price, less the underwriting discounts and commissions.

The Company intends to use the net proceeds from the offering to (i) continue development and regulatory activities, to facilitate commercial readiness, and to commercially launch Recorlev primarily in the United States, (ii) support the life cycle management activities of Keveyis, and (iii) support other general corporate purposes, which may include working capital, capital expenditures, acquisition of additional technologies or other forms of intellectual property, acquisition of assets or businesses that are complementary to our existing business, and general and administrative expenses.

The ordinary shares are being offered and sold pursuant to the Company's shelf registration statement on Form S-3 (File No. 333-223575) (the "Registration Statement"), which was declared effective by the Securities and Exchange Commission (the "Commission") on March 27, 2018, including the prospectus contained therein, as supplemented by a preliminary prospectus supplement, dated September 16, 2020, and a final prospectus supplement, dated September 16, 2020, each filed with the Commission pursuant to Rule 424(b) under the Securities Act of 1933, as amended.

The Underwriting Agreement contains customary representations, warranties and agreements by the Company. Under the terms of the Underwriting Agreement, the Company has agreed to indemnify the Underwriters against certain liabilities. The Company and all of the Company's directors and executive officers have also agreed not to sell or transfer any ordinary shares held by them for a period of 90 days from September 16, 2020 without first obtaining the written consent of the Underwriters, subject to certain exceptions.

The foregoing summary of the Underwriting Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Underwriting Agreement, a copy of which is attached as Exhibit 1.1 hereto and incorporated herein by reference. The Underwriting Agreement contains representations and warranties that the parties made to, and solely for the benefit of, the other in the context of all of the terms and conditions of the Underwriting Agreement and in the context of the specific relationship between the parties. The provisions of the Underwriting Agreement, including the representations and warranties contained therein, are not for the benefit of any party other than the parties to the Underwriting Agreement and are not intended as a document for investors and the public to obtain factual information about the current state of affairs of the parties to those documents and agreements. Rather, investors and the public should look to other disclosures contained in the Company's filings with the Commission.

Item 8.01                      Other Events.

On September 16, 2020, the Company issued a press release announcing the offering and a second press release announcing the pricing of the Offering. Copies of these press releases are filed as Exhibits 99.1 and 99.2, respectively, to this Current Report on Form 8-K and incorporated herein by reference.

In connection with the Offering, the legal opinion as to the legality of the ordinary shares sold is being filed as Exhibit 5.1 to this Current Report on Form 8-K and is incorporated herein and into the Registration Statement by reference.

Item 9.01                      Financial Statements and Exhibits.



(d) Exhibits




Exhibit
Number                                  Exhibit Table

1.1           Underwriting Agreement, dated as of September 16, 2020, by and
            between Strongbridge Biopharma plc and Jefferies LLC and Stifel,
            Nicolaus and Company, Incorporated, as representatives of the several
            underwriters named therein
5.1           Opinion of Arthur Cox
23.1          Consent of Arthur Cox (included in Exhibit 5.1)
99.1          Press Release issued by Strongbridge Biopharma plc, dated September
            16, 2020.
99.2          Press Release issued by Strongbridge Biopharma plc, dated September
            16, 2020.
104         Cover Page Interactive Data File (formatted as inline XBRL).

© Edgar Online, source Glimpses